Financial Performance (Consolidated, ₹ Millions)

Revenue from Operations: ₹10,631 million in Q1 FY27, representing:

  • Year-over-Year (YoY) growth: 39.7% (vs. ₹7,608 million in Q1 FY26)
  • Quarter-over-Quarter (QoQ) growth: 6.0% (vs. ₹10,034 million in Q4 FY26)
  • In USD terms: $112.5 million (26.5% YoY growth, 2.5% QoQ growth)

Profitability:

  • EBITDA: ₹1,795 million (16.9% of revenue)
  • YoY growth: 16.9% (vs. ₹1,536 million)
  • QoQ growth: 8.9% (vs. ₹1,648 million)
  • Profit After Tax (PAT): ₹1,162 million (10.9% of revenue)
  • YoY change: -0.2% (vs. ₹1,164 million)
  • QoQ growth: 45.9% (vs. ₹797 million)
  • Tax expense: ₹365 million (Effective Tax Rate of 23.9%)

Expense Breakdown:

  • Employee Benefit Expenses: ₹6,591 million (36.9% YoY increase)
  • Other Expenses: ₹2,298 million (85.4% YoY increase)
  • Depreciation & Amortization: ₹441 million (104.0% YoY increase)
  • Finance Cost: ₹64 million (72.2% YoY increase)
  • Interest Income: ₹237 million (148.9% QoQ increase)

Exceptional Items: None in Q1 FY27 (compared to ₹203 million provision in Q4 FY26 for estimated cost of settlement of a lawsuit alleging breach of Telephone Consumer Protection Act).

Operational & Business Metrics

Client Metrics:

  • Active Clients (revenue >$0.25M TTM): 105 in Q1 FY27, up from 70 in Q1 FY26 (+50.0% YoY) and 91 in Q4 FY26 (+15.4% QoQ).
  • $1M+ Clients: 54 in Q1 FY27, up from 40 in Q1 FY26 and 43 in Q4 FY26.
  • $10M+ Clients: 12 in Q1 FY27.
  • Top Client Concentration: 9.0% of revenue in Q1 FY27 (vs. 12.4% in Q1 FY26).
  • Top 5 Client Concentration: 30.4% of revenue (vs. 37.9% in Q1 FY26).
  • Top 20 Client Revenue: ₹7,080 million in Q1 FY27 TTM (+9.5% QoQ).
  • Top 5 Client Revenue: ₹3,231 million in Q1 FY27 TTM (+3.4% QoQ).
  • 3 of the top 5 customers now generate over $25 million in revenue.

Employee Metrics:

  • Total Employees: 5,826 (includes overseas contract resources being transitioned)
  • Delivery: 4,983
  • Sales & Support: 843
  • YoY growth: 14.5%
  • Revenue Per Employee (RPE): $77.1K, up 14.2% YoY and 3.2% QoQ.
  • Voluntary Attrition (TTM): 15.7%, down 110 bps YoY.
  • Healthcare Domain Expertise: 29.0% of delivery team, up 420 bps YoY.
  • Women Employees: 46.9% of workforce.

Liquidity Metrics:

  • Days Sales Outstanding (DSO): 67 days, up 4 days YoY and QoQ.
  • Cash & Cash Equivalents: ₹14,602 million (includes current investments and bank deposits).

Revenue Breakdown

By Service Offering (Q1 FY27):

  • Enterprise Commercial Solutions: 70.6% of revenue (₹7,508M; +44.0% YoY)
  • Enterprise Medical Solutions: 25.7% of revenue (₹2,732M; +28.4% YoY)
  • Others: 3.7% of revenue (₹393M; +48.1% YoY)

By Customer Geography (Q1 FY27):

  • North America: 75.1% of revenue (+49.6% YoY)
  • Europe: 22.2% of revenue (+14.3% YoY)
  • India: 0.5% of revenue (+122.0% YoY)
  • Rest of World: 2.2% of revenue (+28.5% YoY)

By Customer Industry (Q1 FY27):

  • Biopharma: 91.6% of revenue (+36.0% YoY)
  • Medical Devices: 3.1% of revenue (+74.9% YoY)
  • Emerging Biotech: 3.3% of revenue (+99.0% YoY)
  • Others: 2.0% of revenue (+160.5% YoY)

Management Commentary

Manish Gupta, Chairman and CEO, and Suhas Prabhu, CFO, provided commentary:

  • FY27 started strongly with the strongest sequential Q1 growth in four years (2.5% USD revenue growth QoQ).
  • Active client base expanded to over 100.
  • Revenue per employee of $77K is stated to be the highest in their peer group.
  • Client relationships deepened, with 12 customers generating over $10 million in annual revenue each.
  • Focus is on developing differentiated products, solutions, and GenAI-powered technologies.
  • Profitability improved sequentially with EBITDA and PAT margin expansion.
  • Operating leverage is expected to improve further in the second half of the year as investments mature and engagements scale.

Strategic Priorities for FY27

1. Move up the clients' value chain to capture more high-value, creative, strategic, and content-creation work.

2. Scale GenAI offerings from concept to revenue-generating engagements (e.g., Generative Engine Optimization, One-Click Submission).

3. Invest in scaling homegrown platforms where domain expertise is embedded into technology (e.g., Medico-Legal Review Platform, Medical Writing Platform, Content Super App).

4. Progressively bring margins back to historical levels as investments convert to revenue, aided by outcome-based deals and embedded GenAI in delivery workflows (Transform AI initiative).

Business Model & Market Context

  • The company describes itself as a "new category" operating at the intersection of healthcare and technology, not fitting traditional IT-services, Agency, or CRO boxes.
  • It acts as an "Embedded Revenue Partner" operating on clients' growth-side budgets.
  • It highlights deep domain expertise (27+ years in life sciences) and a GenAI disruptor strategy.
  • ~60% of revenue is stated to be outcome-aligned.
  • The addressable market is cited as $135+ billion across Life Sciences Operations Spend (Sales, Regulatory, Medical Affairs, Pharmacovigilance).
  • Key industry tailwinds mentioned include rising digital/tech adoption, growth in outsourcing, patent cliff, margin pressures, and increased drug launches.